Drugs / SKI-G-801
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05971862 | Jan 2022 → Apr 2024 | neoplasm | Oscotec Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT03564288 | Feb 2018 → Sep 2021 | acute myeloid leukemia | Oscotec Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SKI-G-801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05971862 ↗ |
| Route | Intravenous | “SKI-G-801 is administered as an IV infusion over 10 minutes” NCT03564288 ↗ |